Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03835481 · ClinicalTrials.gov registry record · Phase 2
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
NCT03835481 is a Phase 2 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 165 participants.
The verdict
NCT03835481, a Phase 2 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
Study Summary
To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
Interventions
- DRUG BI 730357
- DRUG Placebo to match BI 730357
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2021-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03835481
The ClinicalTrials.gov registry entry for NCT03835481 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BI 730357 is the first listed.
NCT03835481 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03835481 about?
NCT03835481 is a clinical study titled "A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is". To assess long-term safety, tolerability, and efficacy of BI 730357 in patients with moderate to severe chronic plaque psoriasis.
What is the current status of trial NCT03835481?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2019-03-18. Estimated completion is 2021-07-27.
What interventions are being tested in trial NCT03835481?
The interventions under investigation include: BI 730357 (DRUG), Placebo to match BI 730357 (DRUG).
Who is sponsoring clinical trial NCT03835481?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.